Screening for obesity in children and adolescents: U.S. Preventive Services Task Force recommendation statement.

GUIDELINE TITLE
Screening for obesity in children and adolescents: U.S. Preventive Services Task Force recommendation statement.

BIBLIOGRAPHIC SOURCE(S)
US Preventive Services Task Force. Screening for obesity in children and adolescents: US Preventive Services Task Force recommendation statement. Pediatrics 2010 Feb;125(2):361-7. PubMed

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: U.S. Preventive Services Task Force (USPSTF). Screening and interventions for overweight in children and adolescents: recommendation statement. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2005. 11 p.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

January 21, 2010 - Meridia (sibutramine hydrochloride): The U.S. Food and Drug Administration (FDA) notified healthcare professionals that the review of additional data indicates an increased risk of heart attack and stroke in patients with a history of cardiovascular disease using sibutramine. Based on the serious nature of the review findings, FDA requested and the manufacturer agreed to add a new contraindication to the sibutramine drug label stating that sibutramine is not to be used in patients with a history of cardiovascular disease.

open here to see the full-text:
Screening for obesity in children and adolescents: U.S. Preventive Services Task Force recommendation statement.